FGI-104

FGI-104
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)-6-[4-(hydroxymethyl)-3-methoxyphenyl]phenol;
PubChem CID	44158960;
ChemSpider	65322076;
Chemical and physical data
Formula	C28H30ClN3O3
Molar mass	492.008 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c4cnc1cc(Cl)ccc1c4Nc(cc2CN(CC)CC)cc(c2O)-c(cc3OC)ccc3CO;
	InChI InChI=1S/C28H30ClN3O3/c1-4-32(5-2)16-20-12-22(31-25-10-11-30-26-14-21(29)8-9-23(25)26)15-24(28(20)34)18-6-7-19(17-33)27(13-18)35-3/h6-15,33-34H,4-5,16-17H2,1-3H3,(H,30,31); Key:OFXBJOIYAJBMNY-UHFFFAOYSA-N;

FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including hepatitis B, hepatitis C, HIV, Ebola virus, and Venezuelan equine encephalitis virus. ^[1]

Mechanism[]

The drug acts by inhibiting the protein TSG101, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease.^[2]^[3]

References[]

^ Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, et al. (January 2009). "FGI-104: a broad-spectrum small molecule inhibitor of viral infection". American Journal of Translational Research. 1 (1): 87–98. doi:10.1016/j.antiviral.2009.02.082. PMC 2776286. PMID 19966942.
^ Janeba Z (November 2015). "Development of Small-Molecule Antivirals for Ebola". Medicinal Research Reviews. 35 (6): 1175–94. doi:10.1002/med.21355. PMC 7168439. PMID 26172225.
^ Saxena A, Ferri M. (2015) Clinical Management of Ebola Virus Disease: Current and Future Approaches. In: Saxena A. (eds) Communicable Diseases of the Developing World. Topics in Medicinal Chemistry, vol 29. Springer, Cham. doi:10.1007/7355_2015_5003

This antiinfective drug article is a stub. You can help Wikipedia by .

[KinchYunus2009-1] Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, et al. (January 2009). "FGI-104: a broad-spectrum small molecule inhibitor of viral infection". American Journal of Translational Research. 1 (1): 87–98. doi:10.1016/j.antiviral.2009.02.082. PMC 2776286. PMID 19966942.

[Janeba2015-2] Janeba Z (November 2015). "Development of Small-Molecule Antivirals for Ebola". Medicinal Research Reviews. 35 (6): 1175–94. doi:10.1002/med.21355. PMC 7168439. PMID 26172225.

[3] Saxena A, Ferri M. (2015) Clinical Management of Ebola Virus Disease: Current and Future Approaches. In: Saxena A. (eds) Communicable Diseases of the Developing World. Topics in Medicinal Chemistry, vol 29. Springer, Cham. doi:10.1007/7355_2015_5003

[1]

[2]

[3]

Legal status

Legal status	US: Investigational New Drug
Identifiers
IUPAC name 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)-6-[4-(hydroxymethyl)-3-methoxyphenyl]phenol
PubChem CID	44158960
ChemSpider	65322076
Chemical and physical data
Formula	C₂₈H₃₀ClN₃O₃
Molar mass	492.008 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES c4cnc1cc(Cl)ccc1c4Nc(cc2CN(CC)CC)cc(c2O)-c(cc3OC)ccc3CO
InChI InChI=1S/C28H30ClN3O3/c1-4-32(5-2)16-20-12-22(31-25-10-11-30-26-14-21(29)8-9-23(25)26)15-24(28(20)34)18-6-7-19(17-33)27(13-18)35-3/h6-15,33-34H,4-5,16-17H2,1-3H3,(H,30,31) Key:OFXBJOIYAJBMNY-UHFFFAOYSA-N

FGI-104

Mechanism[]

See also[]

References[]